SenesTech, Inc. (SNES): Nasdaq/NYSE listing notice — SenesTech receives Nasdaq bid price deficiency notice; 180-day cure period

SenesTech, Inc.

Nasdaq notified SenesTech on Aug 25, 2023 that bid price closed below $1.00 for 30 consecutive business days.
Company has until Feb 21, 2024 to regain compliance; closing bid must be at least $1.00 for 10 consecutive days.
If not cured, SenesTech may qualify for a second 180-day period by meeting other listing standards and showing intent to reverse split.
Notice has no immediate effect on Nasdaq Capital Market listing; company evaluating options.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

SenesTech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

August 25, 2023, we received a letter from the listing qualifications staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) providing notification that the bid price for our common stock had closed below $1.00 per share for the previous 30 consecutive business days and our common stock no longer meets the minimum bid price requirement for continued listing under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have an initial period of 180 calendar days, or until February 21, 2024, to regain compliance. To regain compliance, the closing bid price of

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

SenesTech, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-030680

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.